What is the current stock price of Absci Corporation (ABSI)?

As of the latest market data, Absci Corporation (ABSI) is trading at $2.98. The stock has seen a gain of 1.02% today.

Does Absci Corporation (ABSI) pay a dividend?

Based on current data, Absci Corporation does not have a confirmed active dividend policy.

What is the market cap of Absci Corporation?

The current market capitalization of Absci Corporation (ABSI) is approximately unavailable.

ABSI

Absci Corporation·Healthcare

2.98

1.017%(+0.03)

Market Closed

3.05

2.349%(+0.07)

After Hours

Last Updated: — ET

52W L: $2.2452W H: $5.23

ABSI NEWS

globenewswire.com

3d ago

Absci to Participate in the 25th Annual Needham Virtual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will be participating in the upcoming 25th Annual Needham Virtual Healthcare Conference.

defenseworld.net

Apr 2

MiMedx Group (NASDAQ:MDXG) & Absci (NASDAQ:ABSI) Head to Head Analysis

MiMedx Group (NASDAQ: MDXG - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Volatility and Risk MiMedx Group has a beta

defenseworld.net

Mar 26

Absci Q4 Earnings Call Highlights

Absci (NASDAQ: ABSI) provided a fourth-quarter and full-year 2025 business update on Monday, highlighting early progress for lead candidate ABS-201, expansion into a second indication, and continued investment in its AI-enabled drug creation platform. ABS-201 advances in the clinic with early safety and PK observations Founder and CEO Sean McClain said Absci "had a strong fourth

seekingalpha.com

Mar 25

Absci: Downgrade To 'Hold' As ABS-101 On Back Burner And Pivot To ABS-201

Absci Corporation is downgraded to Hold due to a lack of differentiation for ABS-101 and a strategic pivot to ABS-201. ABS-101 failed to outperform 2nd-generation TL1A candidates, leading to halted internal development and a search for external partnerships. Focus shifts to ABS-201 for androgenetic alopecia, but meaningful efficacy data won't arrive until late 2026 or early 2027.

seekingalpha.com

Mar 24

Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript

zacks.com

Mar 24

Absci Corporation (ABSI) Reports Q4 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.25 per share a year ago.

Company Profile

Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.

Sector

Healthcare

Industry

Biotechnology

Employees

156

IPO Date

2021-07-22

Beta

2.01

Websitewww.absci.com↗